---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-267243"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2023-10-31T23:59:59+00:00"
generated_at: "2026-06-09T05:02:49.896736+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# enGene closes business combination with SPAC Forbion European Acquisition Corp., becomes public on Nasdaq

## Summary
- New enGene shares and warrants trade on Nasdaq under 'ENGN' and 'ENGNW' starting Nov 1, 2023.
- Approximately 10.4 million FEAC Class A shares were redeemed in connection with the deal.
- Post-combination, Forbion Growth (31.9%), Lumira Ventures (14.4%), and others are top shareholders.
- Company retains enGene's focus on non-viral gene therapies for mucosal tissues, lead candidate EG-70 for NMIBC.
- PIPE financing was consummated alongside the transaction (amount not disclosed in this filing).

## SEC filing metadata
- accession: 0001193125-23-267243
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2023-10-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 9.01, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/0001193125-23-267243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-267243
- JSON: https://secwatch.observer/filing/0001193125-23-267243.json
- Plain text: https://secwatch.observer/filing/0001193125-23-267243.txt

## Key facts
- Governance Changes
  enGene Therapeutics Inc.: FEAC and New enGene ceased to be shell companies upon closing of business combination (effective 2023-10-31).
  - Change: shell status
  - Effective: 2023-10-31
  source text: On October 31, 2023, as a result of the consummation of the Business Combination, each of FEAC and New enGene ceased to be a shell company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/0001193125-23-267243-index.htm
- Governance Changes
  enGene Therapeutics Inc.: Adopted new Code of Business Conduct and Ethics on October 31, 2023 (effective 2023-10-31).
  - Change: code of ethics
  - Effective: 2023-10-31
  source text: on October 31, 2023, New enGene’s board of directors approved and adopted a new Code of Business Conduct and Ethics
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/0001193125-23-267243-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.